Relationship between potential doubling time (T(POT)), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure T(POT)?

Radiotherapy and Oncology

Volumn 46, Issue 2, 1998, Pages 157-167

  Haustermans, Karin ^a,b   Fowler, Jack ^a   Geboes, Karel ^a   Christiaens, Marie Rose ^a   Lerut, Antoon ^a   Van Der Schueren, Emmanuel ^a  

^a UZ Gasthuisberg   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast tumors; Esophageal tumors; Flow cytometry; Labeling index; Potential doubling time; Proliferation

Indexed keywords

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST TUMOR; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; DNA SYNTHESIS; ESOPHAGUS BIOPSY; ESOPHAGUS TUMOR; FEMALE; FLOW CYTOMETRY; HUMAN; IRRADIATION; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELIABILITY; TUMOR GROWTH;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MITOTIC INDEX;

EID: 0031936455     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(97)00164-3     Document Type: Article

References (46)

1. Altman, D.G. Practical Statistics for Medical Research, pp. 404-409. Chapman and Hall, London, 1991.
2. Awwad, H.K. Unconventional fractionation studies and Tpot correlation. Semin. Radiat. Oncol. 2: 62-66, 1992, and update at Int. Cancer Congress, December 1994.
3. Begg, A.C., Hofland, I., Van Glabekke, M., Bartelink, H. and Horiot, J.C. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol. 2: 22-25, 1992.
4. Begg, A.C., McNally, N.J., Shrieve, D.C. and Kaercher, H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6: 620-626, 1985.
5. Begg, A.C., Wilson, G.D. and Hart, G. Meta-analysis of the correlation of Tpot with clinical outcome in patients treated by conventional radiotherapy in 9 European centres. ECCO meeting abstract, Paris, 1995.
6. Bentzen, S.M. and Thames, H.D. Overall treatment time and tumor control dose for head and neck tumors: the dogleg revisited. Radiother. Oncol. 25: 143-144, 1992.
7. Bland, J.M. and Altman, D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i, 307-310, 1986.
8. Bonnadonna, G., Valagussa, P., Tancini, G., Rossi, A., Brambilla, C., Zambetti, M., Bignami, P., Di Fronzo, G. and Silvestrini, R. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. Natl. Cancer Inst. Monogr. 1: 45-49, 1986.
9. Bourhis, J., Dendale, R., Hill, C., Bosq, J., Janot, F., Attal, P., Fortin, A., Marandas, P., Schwaab, G., Wibault, P., Malaise, E.P., Bobin, S., Luboinski, B., Eschwege, F. and Wilson, G.D. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 Gy in 7 weeks. Int. J. Radiat. Oncol. Biol. Phys. 35: 471-475, 1996.
10. Brennan, P. and Silman, A. Statistical methods for assessing observer variability in clinical measures. Br. Med. J. 304: 1491-1494, 1992.
11. Chappell, R., Nondahl, D., Fowler, J.F. and Rezvani, M. Further analysis of radiobiological parameters from the first and second British Institute of Radiology randomized studies of larynx/pharynx radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1995.
12. Cohen, J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas. 20: 37-46, 1960.
13. Corvo, R., Giaretti, W., Sanguineti, G., Geido, E., Orecchia, R., Guenzi, M., Margarino, G., Bacigalupa, A., Garaventa, G., Barbieri, M. and Vitale, V. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J. Clin. Oncol. 13: 1843-1850, 1995.
14. Courdi, A., Hery, M., Dahan, E., Gioanni, J., Abbes, M., Monticelli, J., Ettore, F., Moll, J.L. and Namer, M. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. Eur. J. Cancer Clin. Oncol. 25: 351-356, 1989.
15. Cox, J.D., Pajak, T.F., Asbell, S., Russell, A.H., Pederson, J., Byhardt, R.W., Emami, B. and Roach, M. Interruptions of high dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from three RTOG trials. Int. J. Radiat. Oncol. Biol. Phys. 27: 493-498, 1993.
16. Cyr, L. and Francis, K. Measures of clinical agreement for nominal and categorical data: the kappa coefficient. Comput. Biol. Med. 22: 239-246, 1992.
17. Fowler, J.F. and Lindstrom, M.J. Loss of local control with prolongation in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23: 457-467, 1992.
18. Fyles, A., Keane, T.J., Barton, M. and Simm, J. The effect of treatment duration on local control of squamous cell carcinoma of the tonsil and carcinoma of the cervix. Semin. Radiat. Oncol. 2: 22-28, 1992.
19. Girinsky, T., Rey, A., Roche, B., Haie, C., Gerbaulet, A., Randrianrivello, H. and Chassagne, D. Overall treatment time in advanced cervical carcinomas. A critical parameter in treatment outcome. Int. J. Radiat. Oncol. Biol. Phys. 27: 1051-1056, 1993.
20. Haustermans, K., Vanuytsel, L., Geboes, K., Lerut, T., Van Thillo, J., Leysen, J., Coosemans, W. and van der Schueren, E. In vivo cell kinetic measurements in human oesophageal cancer: what can be learned from multiple biopsies? Eur. J. Cancer 30A: 1787-1791, 1994.
21. Haustermans, K. In vivo growth kinetic measurements in human esophageal cancer. Thesis, Faculty of Medicine, Katholieke Universiteit Leuven, 1995.
22. Hendry, J.H., Bentzen, S.M., Dale, R.G., Fowler, J.F., Wheldon, T.E., Jones, B., Munro, A.J., Slevin, N.J. and Robertson, A.G. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin. Oncol. 8: 297-307, 1996.
23. Hendry, J.H., Roberts, S.A., Slevin, N.J., Keane, T.J., Barton, M.B. and Agren-Conqvist, A. Influence of radiotherapy treatment time on control of laryngeal cancer: comparisons between centres in Manchester, UK and Toronto, Canada. Radiother. Oncol. 31: 14-22, 1994.
24. Lanciano, R.M., Pajak, T.F., Martz, K. and Hanks, G.E. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns of care study. Int. J. Radiat. Oncol. Biol. Phys. 25: 391-397, 1993.
25. Landis, J.R. and Koch, G.C. The measurement of observer agreement for categorical data. Biometrics 33: 159-174, 1977.
26. McDivitt, R.W., Stone, K.R., Craig, R.B., Palmer, J.O., Meyer, J.S. and Bauer, W.C. A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers. Cancer 57: 269-276, 1986.
27. Metz, C.E., Tokars, R.P., Kronman, H.B. and Griem, M.L. Maximum likelihood estimation of dose-response parameters for therapeutic operating characteristic (TOC) analysis of carcinoma of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 8: 1185-1192, 1982.
28. Metz, C.E. Basic principles of ROC analysis. Semin. Nucl. Med. 8: 283-298, 1978.
29. Meyer, J.S. and Province, M. Proliferative index of breast carcinoma by thymidine labeling: prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res. Treat. 7: 161-169, 1986.
30. Mussurakis, S., Buckley, D.L., Coady, A.M., Turnbull, L.W. and Horsman, A. Observer variability in the interpretation of contrast enhanced MRI of the breast. Br. J. Radiol. 69: 1009-1016, 1996.
31. Perez, C.A., Grigsby, P.W., Castro-Vita, H. and Lockett, M.A. Carcinoma of the uterine cervix I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 32: 1275-1288, 1995.
32. Petereit, D.G., Sarkaria, J.N., Chappell, R., Fowler, J.F., Hartmann, T.J., Kinsella, T.J., Stitt, J.A., Thomadsen, B. and Buchler, D.A. The adverse effect of treatment prolongation in cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 32: 1301-1307, 1995.
33. Rew, D.A., Campbell, I.D., Taylor, I. and Wilson, G.D. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2′-deoxyuridine labeling: a flow cytometric study of 75 tumours. Br. J. Surg. 79: 335-339, 1992.
34. Robertson, C., Robertson, A.G., Hendry, J.H., Roberts, S.A., Slevin, N.J., Duncan, W.B., MacDougall, H., Kerr, G. and Keane, T.J. The effect of overall treatment time and unplanned gaps on local control of carcinoma of the larynx treated by radiotherapy in four centres. Int. J. Radiat. Oncol. Biol. Phys., in press, 1997.
35. Saunders, M.I., Dische, S., Barrett, A., Parmar, M.K.B., Harvey, A. and Gibson, D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell cancer: an interim report. Br. J. Cancer 73: 1455-1462, 1996.
36. Silvestrini, R., Daidone, M.G. and Gasparini, G. Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982-1987, 1985.
37. Silvestrini, R., Daidone, M.G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G., Andreola, S., Salvadori, B. and Veronesi, U. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol. 13: 697-704, 1995.
38. Silvestrini, R., Daidone, M.G., Valagussa, P., Di Fronzo, G., Mezzanotte, G. and Bonnadonna, G. Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur. J. Cancer Clin. Oncol. 25: 1165-1171, 1989.
39. Silvestrini, R., Daidone, M.G., Valagussa, P., Salvadori, B., Revini, D. and Bonnadonna, G. Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat. Rep. 71: 375-379, 1987.
40. Steel, G.G. Growth Kinetics of Tumours, pp. 191 and 202. Clarendon Press, Oxford, 1977.
41. Swets, J.A., Tanner, W.P. and Birdsall, T.G. Decision processes in perception. In: Signal Detection and Recognition by Human Observers, pp. 3-57. Wiley, New York, 1964.
42. Wilson, G.D. Assessment of human tumour proliferation using bromodeoxyuridine - current status. Acta Oncol. 30: 903-910, 1991.
43. Wilson, M.S., West, C.M.L., Wilson, G.D., Roberts, S.A., James, R.D. and Schofield, P.F. An assessment of the reliability and reproducibility of measurement of potential doubling times (Tpot) in human colorectal tumours. Br. J. Cancer 67: 754-759, 1993.
44. Wilson, M.S., West, C.M.L., Wilson, G.D., Roberts, S.A., James, R.D. and Schofield, P.F. Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer. Br. J. Cancer 68: 501-506, 1993.
45. Withers, H.R., Taylor, J.M.G. and Maciejewski, B. The hazard of tumor clonogen repopulation during radiotherapy. Acta Oncol. 27: 131-146, 1988.
46. Zackrisson, B., Flygare, P., Gustafsson, H., Stenling, R. and Wilson, G.D. The predictive value of potential doubling time in head and neck cancer patients treated by conventional radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 38: 667-683, 1997.